Short Interest in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Rises By 7.3%

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) was the target of a large growth in short interest in November. As of November 15th, there was short interest totalling 7,370,000 shares, a growth of 7.3% from the October 31st total of 6,870,000 shares. Based on an average daily volume of 415,400 shares, the days-to-cover ratio is currently 17.7 days.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. HC Wainwright reissued a "buy" rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Monday, October 7th. Cantor Fitzgerald restated an "overweight" rating on shares of KalVista Pharmaceuticals in a research report on Monday, September 9th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $32.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, September 6th.

KalVista Pharmaceuticals Stock Down 5.3 %

KALV stock traded down $0.54 during midday trading on Tuesday, reaching $9.73. The company had a trading volume of 216,674 shares, compared to its average volume of 440,255. KalVista Pharmaceuticals has a 1-year low of $7.39 and a 1-year high of $16.88. The stock has a 50 day moving average price of $10.96 and a 200-day moving average price of $11.89.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last issued its earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.04. Sell-side analysts anticipate that KalVista Pharmaceuticals will post -2.7 EPS for the current fiscal year.

Insider Buying and Selling

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 8,077 shares of the stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $74,793.02. Following the completion of the transaction, the insider now owns 94,199 shares in the company, valued at approximately $872,282.74. This represents a 7.90 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Benjamin L. Palleiko sold 7,352 shares of the business's stock in a transaction on Monday, September 9th. The stock was sold at an average price of $12.19, for a total transaction of $89,620.88. Following the completion of the sale, the chief executive officer now directly owns 250,800 shares in the company, valued at approximately $3,057,252. This represents a 2.85 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 32,016 shares of company stock worth $319,344 in the last quarter. 10.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. nVerses Capital LLC acquired a new stake in KalVista Pharmaceuticals in the second quarter valued at about $25,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of KalVista Pharmaceuticals by 67.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company's stock valued at $96,000 after purchasing an additional 3,328 shares in the last quarter. Intech Investment Management LLC bought a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter valued at approximately $126,000. SG Americas Securities LLC acquired a new position in KalVista Pharmaceuticals during the 3rd quarter worth approximately $153,000. Finally, Quest Partners LLC bought a new position in KalVista Pharmaceuticals in the 3rd quarter valued at approximately $175,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).